MedPath

Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg

Phase 4
Completed
Conditions
Non-erosive Reflux Disease(NERD)
Interventions
Drug: EsoDuo Tab. 20/800mg
Registration Number
NCT03928470
Lead Sponsor
Chong Kun Dang Pharmaceutical
Brief Summary

To Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg

Detailed Description

A multicenter, randomized, double-blind, active-controlled phase 4 study to evaluate the efficacy and safety of EsoDuo Tab. 20/800mg in patients with non-erosive reflux disease(NERD)

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
379
Inclusion Criteria
  1. Male or Female aged ≥ 19 years
  2. Episode of heartburn for 3 months or more during prior to randomization visit.
  3. Episode of heartburn for 2 days or more during the last 7 days prior to randomization visit.
  4. Grade N, M by EGD test.
Read More
Exclusion Criteria
  1. Surgery history on stomach or esophagus
  2. Active medical history of stomach, esophagus area
  3. Other system disorder which can disturb this trial
  4. Patients taking the contraindication of concomitant medications
  5. Clinically significant Abnormal Lab test
  6. Pregnant woman, Breastfeeding woman.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
EsoDuo Tab. 20/800mgEsoDuo Tab. 20/800mgEsoDuo Tab. 20/800mg
Nexium Tab. 20mgEsoDuo Tab. 20/800mgNexium Tab. 20mg
Primary Outcome Measures
NameTimeMethod
Complete resolution of heartburn(HB), Last 7 days of treatment, 4 weeks.4 weeks after drug administrations.

Compare Experimental group with Active Comparator.

Secondary Outcome Measures
NameTimeMethod
Complete resolution of heartburn(HB), Last 7 days of treatment, 2 weeks.2 weeks after drug administrations

Compare Experimental group with Active Comparator.

Complete resolution of Acid regurgitation, Last 7 days of treatment, 2 / 4 weeks.2/4 weeks after drug administrations.

Compare Experimental group with Active Comparator.

The percentage of Heartburn(HB) / Acid regurgitation only 1 day or less free days, 2 / 4 weeks.2/4 weeks after drug administrations.

Compare Experimental group with Active Comparator.

The percentage of free days without Heartburn(HB) / Acid regurgitation, 2 / 4 weeks.2/4 weeks after drug administrations.

Compare Experimental group with Active Comparator.

The time to the first 24/48-h, 7-d of Heartburn(HB) / Acid regurgitation free interval.2/4 weeks after drug administrations.

Compare Experimental group with Active Comparator.

Change from baseline in the Heartburn(HB) / Acid regurgitation Symptom score, 2 / 4 weeks.2/4 weeks after drug administrations.

Compare Experimental group with Active Comparator.

Heartburn(HB) / Acid regurgitation symptoms per investigator assessment, 4weeks.4 weeks after drug administrations.

Compare Experimental group with Active Comparator.

Time to first resolution of Heartburn(HB), Day 11 day after drug administrations.

Compare Experimental group with Active Comparator.

Trial Locations

Locations (38)

Dong-A University Hospital

🇰🇷

Busan, Korea, Republic of

Kosin University Gospel Hospital

🇰🇷

Busan, Korea, Republic of

Hallym University Chuncheon Seonsim Hospital

🇰🇷

Chuncheon, Korea, Republic of

Ajou University Hospital

🇰🇷

Gyeonggi-do, Korea, Republic of

Chungbuk National University Hospital

🇰🇷

Cheongju, Korea, Republic of

Chungnam National University Hospital

🇰🇷

Daejeon, Korea, Republic of

Soonchunhyang University Cheonan Hospital

🇰🇷

Cheonan, Korea, Republic of

Gachon Gil Hospital

🇰🇷

Incheon, Korea, Republic of

Daegu Catholic Hospital

🇰🇷

Daegu, Korea, Republic of

Myongji Hospital

🇰🇷

Goyang, Korea, Republic of

Hanyang University Guri Hospital

🇰🇷

Gyeonggi-do, Korea, Republic of

Inje University Busan Paik Hospital

🇰🇷

Pusan, Korea, Republic of

Pusan National University Hospital

🇰🇷

Pusan, Korea, Republic of

Yangsan Pusan National University Hospital

🇰🇷

Pusan, Korea, Republic of

Gangnam Severance

🇰🇷

Seoul, Korea, Republic of

Konkuk University Hospital

🇰🇷

Seoul, Korea, Republic of

Yeungnam University Medicar Center

🇰🇷

Daegu, Korea, Republic of

Keimyung University Dongsan Medical Center

🇰🇷

Daegu, Korea, Republic of

Chonnam National University Hospital

🇰🇷

Gwangju, Korea, Republic of

Soonchunhyang University Bucheon Hospital

🇰🇷

Gyeonggi-do, Korea, Republic of

Inje University ilsan Paik Hospital

🇰🇷

Gyeonggi-do, Korea, Republic of

Jeju National University Hospital

🇰🇷

Jeju, Korea, Republic of

Chonbuk National University Hospital

🇰🇷

Jeonju, Korea, Republic of

Dongguk University IIsan Hospital

🇰🇷

Ilsan, Korea, Republic of

Wonkwang University Hospital

🇰🇷

Iksan, Korea, Republic of

Asan Medical Center, Seoul

🇰🇷

Seoul, Korea, Republic of

Korea University Anam Hospital

🇰🇷

Seoul, Korea, Republic of

Inje University Haeundae Paik Hospital

🇰🇷

Pusan, Korea, Republic of

Catholic University Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Chung Ang University Hospital

🇰🇷

Seoul, Korea, Republic of

Hanyang University Hospital

🇰🇷

Seoul, Korea, Republic of

Samsung Seoul Hospital

🇰🇷

Seoul, Korea, Republic of

Soonchunhyang University Seoul Hospital

🇰🇷

Seoul, Korea, Republic of

Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Wonju Severance Christian Hospital

🇰🇷

Wŏnju, Korea, Republic of

Korea University Guro Hospital

🇰🇷

Seoul, Korea, Republic of

Kyunghee Universtiy Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath